Table 2.
Treatment received.
| Index therapy, n (%) |
First-line therapy, n (%) |
Second-line therapy, n (%) |
|
|---|---|---|---|
| EGFR TKIa | 246 (100.0) | 226 (91.9) | 52 (37.1) |
| Afatinib | 132 (53.7) | 126 (55.8) | 11 (21.2) |
| Gefitinib | 70 (28.5) | 65 (28.8) | 6 (11.5) |
| Erlotinib | 35 (14.2) | 28 (12.4) | 14 (26.9) |
| Osimertinib | 7 (2.8) | 5 (2.2) | 21 (40.4) |
| Afatinib/gefitinib | 1 (0.4) | 1 (0.4) | 0 |
| Gefitinib/erlotinib | 1 (0.4) | 1 (0.4) | 0 |
| Chemotherapyb | — | 21 (8.5) | 84 (60.0) |
| Chemo-immunotherapy | — | — | 4 (2.9) |
One patient was treated with gefitinib plus chemotherapy, 27 patients received additional radiotherapy, 1 patient denosumab.
Three patients received chemotherapy + bevacizumab, 12 patients received additional radiation.
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.